Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

Daniel Drucker, the Canadian scientist renowned for discoveries that sparked the advent of Ozempic and other GLP-1 medicines ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Reduced frequency is very encouraging for patient compliance and could help those who dislike weekly injections and ...

Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in ...

Together, these data demonstrate the versatility of the NanoPortal technology beyond NPM-115 (exenatide implant) and provide ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...

Recently the United States federal government cancelled $400 million dollars in grants to Columbia University, with $250 ...